Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (18)

2019

  1. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

2017

  1. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

    Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321

  2. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts

    British Journal of Dermatology, Vol. 176, Núm. 3, pp. 643-649

2016

  1. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis

    Journal of the European Academy of Dermatology and Venereology, Vol. 30, Núm. 11, pp. 1942-1950

  2. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881

  2. Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time

    Actas Dermo-Sifiliograficas, Vol. 106, Núm. 8, pp. 638-643

  3. Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time

    Actas dermo-sifiliograficas, Vol. 106, Núm. 8, pp. 638-643

  4. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 29, Núm. 1, pp. 156-163

  5. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: An observational study from national BIOBADADERM registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 29, Núm. 5, pp. 858-864

  6. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice

    Journal of Dermatological Treatment, Vol. 26, Núm. 6, pp. 502-506

2014

  1. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: Results of the Biobadaderm Registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 28, Núm. 7, pp. 907-914

2013

  1. Guidelines for the use of acitretin in psoriasis

    Actas Dermo-Sifiliograficas

  2. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: A study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 27, Núm. 11, pp. 1366-1374

2012

  1. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: Patients ineligible vs eligible for randomized controlled trials

    Archives of Dermatology, Vol. 148, Núm. 4, pp. 463-470

  2. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes

    Human Molecular Genetics, Vol. 21, Núm. 20, pp. 4549-4557

2010

  1. Guidelines on the use of methotrexate in psoriasis

    Actas Dermo-Sifiliograficas, Vol. 101, Núm. 7, pp. 600-613

1995

  1. SINDROME DE SOLAPAMIENTO ESCLERODERMIA-DERMATOMIOSITIS: A PROPOSITO DE UN CASO SIN MARCADORES INMUNOLOGICOS

    Actas Dermo-Sifiliograficas, Vol. 86, Núm. 1-2, pp. 22-27